Although we intend to target North American or European companies, our focus will be to acquire a business in the healthcare industry in the United States. We believe the healthcare industry, particularly the life sciences sector, represents an enormous and growing target market with a large number of potential target acquisition opportunities. More specifically, we intend to target companies in the biopharmaceutical sector. Since the beginning of 2020, over 85 SPACs focusing within the broader healthcare market have been formed, over 50 of which were this year, according to SPAC Analytics (as of Oct. 11, 2021).

Our founders have 120 years of combined experience in the life sciences. Marc F. Pelletier, PhD (Chief Executive Officer, co-founder) and Paul R. McGuirk, PhD (Chief Development Officer, co-founder) worked recently together on Aeromics, Inc., and Frank C. Sciavolino, PhD (board member, co-founder) co-founded Thetis Pharmaceuticals with Greg Gardiner, our company’s namesake. Prior to launching Aeromics and Thetis, Paul R. McGuirk and Frank C. Sciavolino held senior positions at Pfizer, Executive Director and Vice President of R&D Operations, respectively, and were responsible for four marketed drugs at Pfizer, with over $25 billion in sales. Marc F. Pelletier also co-founded Iridia, Inc., a company that is developing DNA-based memory chips.

(Note: Gardiner Healthcare Acquisition Corp. priced its SPAC IPO on Dec. 21, 2021, in line with the terms in its prospectus: 7.5 million units at $10 each to raise $75 million.)